Comparison of Current Immunotherapy Approaches and Novel Anti-Cancer Vaccine Modalities for Clinical Application

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Cancer remains a significant global health burden with increasing incidence in younger populations, particularly drug-resistant colorectal cancer.
• Current immunotherapies like checkpoint inhibitors face limitations due to the tumor microenvironment and lack of specificity.
• Therapeutic cancer vaccines represent an innovative approach with potential for long-term efficacy and disease recurrence prevention.

Purpose of the Study:

• To review current immunotherapy options in cancer treatment.
• To discuss recent advances in anti-cancer vaccine development and modalities.
• To explore the potential of therapeutic vaccines in combination with emerging technologies like AI.

Main Methods:

• Review of current literature on cancer immunotherapy and vaccine development.
• Discussion of novel vaccine production techniques, including gene editing and bioprocessing.
• Exploration of different vaccine types: protein-based subunit, virus-like particle, viral vector, and nucleic acid-based (RNA/DNA).

Main Results:

• Therapeutic vaccines can activate cytotoxic T cells and helper T cells to generate immune memory against cancer.
• Advances in vaccine technology enable the creation of diverse and targeted anti-cancer vaccines.
• The integration of machine learning and artificial intelligence holds potential to enhance vaccine efficacy.

Conclusions:

• Cancer vaccines offer a promising strategy for monotherapy and combination treatment in oncology.
• Future directions involve leveraging advanced vaccine platforms and AI to overcome immunotherapy challenges.
• Cancer vaccines have the potential to revolutionize oncology and improve patient prognosis.